Showing results (381-390 of 447) with videos related to
Sort By:
Pageof 45
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup TrialTim Eisen, Eleni Frangou, Bhavna Oza, et al.Journal for Immunotherapy of Cancer|September 29, 2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, et al.Nature Cancer|February 5, 2022
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studyAnnika Fendler, Lewis Au, Scott T C Shepherd, et al.Research Square|September 28, 2021
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studyAnnika Fendler, Lewis Au, Scott T C Shepherd, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial ResultsAdi Diab, Helen Gogas, Shahneen Sandhu, et al.Melanoma Research|July 31, 2015
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patientsSaif S Ahmad, Wendi Qian, Sarah Ellis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced MelanomaGeorgina V Long, James Larkin, Dirk Schadendorf, et al.Contemporary Clinical Trials|September 20, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma settingAngela Meade, Bhavna Oza, Eleni Frangou, et al.Contemporary Clinical Trials|September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapseBhavna Oza, Eleni Frangou, Ben Smith, et al.Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.Pageof 45